Javascript must be enabled to continue!
BCG Revaccination to Combat Tuberculosis Infection: an Evidence Based Case Report
View through CrossRef
An elderly man came to the Emergency Room with labored breathing with a history of prior tuberculosis infection and BCG vaccination when he was an infant. He was diagnosed with tuberculosis reinfection with negative microbiology result. This study aims to see whether revaccination of BCG vaccination will positively impact suppressing the rate of tuberculosis infection. A literature search was conducted on three databases: PubMed, Cochrane, and EBSCOhost. Of the searches, three articles were selected for further critical appraisal using the criteria provided by the University of Oxford Centre of Evidence-Based Medicine. The first study shows that BCG Revaccination does not become a protective factor against tuberculosis reinfection with OR 0.92 (0.80 – 1.05) in all populations yet interestingly yielded OR 0.77 (0.59-1.00) in HIV-negative patients, while the second study shows that BCG Revaccination can prevent conversion of QFT with the study showing p <0.05, thus believed to lower tuberculosis infection rates, the third study shows that BCG revaccination yield modest protection against TB infection after 15 years (Hazard Ratio 0.64 95% CI 0.46-0.89). The main difference between the studies is the main population, which the first study also includes HIV-positive patients. In conclusion, BCG Revaccination may be considered to be given and be considered as protective factor against tuberculosis reinfection in HIV-negative patients.
Title: BCG Revaccination to Combat Tuberculosis Infection: an Evidence Based Case Report
Description:
An elderly man came to the Emergency Room with labored breathing with a history of prior tuberculosis infection and BCG vaccination when he was an infant.
He was diagnosed with tuberculosis reinfection with negative microbiology result.
This study aims to see whether revaccination of BCG vaccination will positively impact suppressing the rate of tuberculosis infection.
A literature search was conducted on three databases: PubMed, Cochrane, and EBSCOhost.
Of the searches, three articles were selected for further critical appraisal using the criteria provided by the University of Oxford Centre of Evidence-Based Medicine.
The first study shows that BCG Revaccination does not become a protective factor against tuberculosis reinfection with OR 0.
92 (0.
80 – 1.
05) in all populations yet interestingly yielded OR 0.
77 (0.
59-1.
00) in HIV-negative patients, while the second study shows that BCG Revaccination can prevent conversion of QFT with the study showing p <0.
05, thus believed to lower tuberculosis infection rates, the third study shows that BCG revaccination yield modest protection against TB infection after 15 years (Hazard Ratio 0.
64 95% CI 0.
46-0.
89).
The main difference between the studies is the main population, which the first study also includes HIV-positive patients.
In conclusion, BCG Revaccination may be considered to be given and be considered as protective factor against tuberculosis reinfection in HIV-negative patients.
Related Results
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Apoptosis Activity of the Mouse Macrophage Cell Line J774A.1 Infected with a Recombinant BCG consisting the C-Terminus of Merozoite Surface Protein-1 of Plasmodium falciparum
Apoptosis Activity of the Mouse Macrophage Cell Line J774A.1 Infected with a Recombinant BCG consisting the C-Terminus of Merozoite Surface Protein-1 of Plasmodium falciparum
Macrophage apoptosis exerts an efficient mechanism in controlling intracellular infection during innate immune response against various pathogens including malaria parasites. This ...
A novel Mycobacterium tuberculosis-specific subunit vaccine provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin
A novel Mycobacterium tuberculosis-specific subunit vaccine provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin
ABSTRACT
Tuberculosis (TB) remains a global health crisis. Following encouraging clinical results of subunit vaccination and revaccination with Bacillus Calmette-Gu...
Bacillus Calmette-Guérin Revaccination Questionable with Low Tuberculosis Incidence
Bacillus Calmette-Guérin Revaccination Questionable with Low Tuberculosis Incidence
Abstract
Bacillus Calmette-Guérin (BCG) revaccination was discontinued in Finland in 1990. The objective of this study was to assess the impact of BCG revaccinati...
Faktor yang berhubungan dengan kejadian tuberkulosis paru pada anak (usia 0-14 tahun)
Faktor yang berhubungan dengan kejadian tuberkulosis paru pada anak (usia 0-14 tahun)
Background: Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis and can affect all ages, including children. The incidence of pulmonary TB...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Systematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosis
Systematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosis
Introduction
Tuberculosis (TB) is a disease caused by
Mycobacterium tuberculosis
(M.TB) and o...
Mantoux test results and BCG vaccination status in TB-exposed children
Mantoux test results and BCG vaccination status in TB-exposed children
Background Tuberculosis (TB) infection is highly prevalent in Indonesia. The source of transmission of TB to a child is usually via an adult with sputum smear-positive pulmonary tu...

